Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Intravesical gene therapy
12 evidence topics · 8 sources
Guideline description: nadofaragene firadenovec
Nadofaragene firadenovec: labeled indication
Nadofaragene firadenovec: dosing and administration
Nadofaragene firadenovec: efficacy in the pivotal trial (label)
| Efficacy outcome measure (Study CS-003) | Adstiladrin (n=98) |
|---|---|
| Complete response rate | “51%” |
| 95% CI | “(41%, 61%)” |
| Median duration of response in months (range) | “9.7 (3, 52+)” |
| Duration of response ≥ 12 months | “46%” |
Nadofaragene firadenovec: phase 3 trial results by cohort
“55 (53·4%) of 103 patients with carcinoma in situ (with or without a high-grade Ta or T1 tumour) had a complete response within 3 months of the first dose and this response was maintained in 25 (45·5%) of 55 patients at 12 months. Micturition urgency was the most common grade 3–4 study drug-related adverse event (two [1%] of 157 patients, both grade 3), and there were no treatment-related deaths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the high-grade Ta or T1 cohort, 35 of 48 patients (72·9%; 95% CI 58·2 to 84·7) were high-grade recurrence-free at month 3, and 21 patients (43·8%; 29·5 to 58·8) were recurrence-free at month 12.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nadofaragene firadenovec: 5-year follow-up of the phase 3 trial
“Median follow-up was 50.8 months (interquartile range 39.1-60.0), with 27% receiving ≥ 5 instillations and 7.6% receiving treatment for ≥ 57 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Kaplan-Meier–estimated HGRF survival at 57 months was 13% (95% CI 6.9-21.5) and 33% (95% CI 19.5-46.6) in the CIS and Ta/T1 cohorts, respectively. Cystectomy-free survival at month 60 was 49% (95% CI 40.0-57.1): 43% (95% CI 32.2-53.7) in the CIS cohort and 59% (95% CI 43.1-71.4) in the Ta/T1 cohort. Overall survival at 60 months was 80% (71.0, 86.0): 76% (64.6-84.5) and 86% (70.9-93.5) in the CIS and Ta/T1 cohorts, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Most adverse events were grades 1 or 2 (66%), with 3.8% of patients reporting grade 3 events and no patients experiencing grades 4 or 5 study-drug related adverse events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nadofaragene firadenovec: FDA approval summary
“On December 16, 2022, the FDA approved the adenoviral vector-based gene therapy nadofaragene firadenovec-vncg (brand name Adstiladrin) for the treatment of adult patients with high-risk bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fifty subjects experienced CR 3 months after initial treatment (CR=51%; 95% CI: 40.7; 61.3%), of whom 46% remained in response for ≥12 months. The median DoR was 9.7 months (range: 3 to 52+).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nadofaragene firadenovec: adverse reactions in the pivotal trial
Nadofaragene firadenovec: warnings on delayed cystectomy and disseminated adenovirus infection
Nadofaragene firadenovec: real-world outcomes at a multisite academic center
“Of 24 evaluable patients with carcinoma in situ with/without papillary disease, 79% had a CR at 3 months. The median response duration was not reached; 68% (13/19) of responders still had CRs with median follow-up of 9.3 months. Of 19 patients with papillary-only disease (median follow-up of 7.6 months), HGRFS at 3, 6, and 12 months was 68%, 53%, and 26%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most common adverse events were grade 1–2 bladder spasms (61%) and failure to fully retain the instillation (33%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote